Monthly Archives: April 2018

Sjogren’s Syndrome Foundation cuts diagnosis time in half and the positive impact on existing patients

SS patients know well the difficulty of obtaining a diagnosis. The symptoms of SS are often ascribed to other maladies, side effects, or natural aging. The diversity of symptoms means that many doctors, dentists, optometrists, and specialists see only part

Posted in Diagnosis, Publicity, Research, Treatment Tagged with:

ImmuPharma’s Lupuzor fails to meet the primary endpoint in its phase 3 trial

I woke to extremely disappointing news this morning. In my Hope for 2016 post, I mentioned peptide based drugs as my #2 hope, with Lupuzor being the key candidate. Over the past several years, I have watched the Lupuzor trials

Posted in Clinical Trials, Treatment Tagged with: ,

Plaquenil/hydroxychloroquine may have more extraglandular benefits for Sjogren’s Syndrome patients

Hydroxychloroquine (generic Plaquenil) is often prescribed off-label by doctors for Sjogren’s Syndrome patients despite the fact that it has never been approved by governing agencies like the FDA. I myself have taken hydroxychloroquine for several years. Studies have generally found that hydroxychloroquine

Posted in Research, Treatment, Uncategorized Tagged with: ,
WordPress Appliance - Powered by TurnKey Linux